Get started
Author

Malgorzata Gorniak

Observed names: M Gorniak, M. B. Gorniak, M. Gorniak, Malgorzata B. Gorniak, Małgorzata Gorniak-Walas
ORCID: 0000-0003-1236-8622
Observed ORCID: 0000-0003-1236-8622
OpenAlex ID: A5053155809
Splenectomy Associated Changes in IgM Memory B Cells in an Adult Spleen Registry Cohort
2011 · Paul U. Cameron, Penelope Jones, et al. · PLoS ONE · 119
PDF
HorTILLUS—A Rich and Renewable Source of Induced Mutations for Forward/Reverse Genetics and Pre-breeding Programs in Barley (Hordeum vulgare L.)
2018 · Miriam E. Szurman-Zubrzycka, Justyna Zbieszczyk, et al. · Frontiers in Plant Science · 76
A Reverse-Genetics Mutational Analysis of the Barley HvDWARF Gene Results in Identification of a Series of Alleles and Mutants with Short Stature of Various Degree and Disturbance in BR Biosynthesis Allowing a New Insight into the Process
2016 · Damian Gruszka, Malgorzata Gorniak, et al. · International Journal of Molecular Sciences · 29
PDF
Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis
2022 · Kah Teong Soh, Neil Came, et al. · Cytometry Part B Clinical Cytometry · 27
PDF
Ttyh1 Protein is Expressed in Glia In Vitro and Shows Elevated Expression in Activated Astrocytes Following Status Epilepticus
2014 · Elzbieta Wiernasz, Aleksandra Kaliszewska, et al. · Neurochemical Research · 26
PDF
Correlation between a 10‐color flow cytometric measurable residual disease ( MRD ) analysis and molecular MRD in adult B‐acute lymphoblastic leukemia
2021 · Jasmine Singh, Malgorzata Gorniak, et al. · Cytometry Part B Clinical Cytometry · 13
PDF
The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice
2022 · Rose Turner, Anna Kalff, et al. · Frontiers in Oncology · 9
PDF
A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia
2014 · A. Kalff, T. Khong, et al. · Haematologica · 8
PDF
Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma
2017 · A P Nair, P Walker, et al. · Bone Marrow Transplantation · 6
Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma
2024 · Jessie Zhao, Tiffany Khong, et al. · Haematologica · 4
PDF
Laboratory validation and clinical utility of next-generation sequencing-based IGH/TCR clonality testing for the monitoring of measurable residual disease in acute lymphoblastic leukaemia: real-world experience at Austin Pathology
2024 · Stephen B. Ma, Wendi Lin, et al. · Pathology · 4
Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma
2020 · Joanne L. C. Tan, Tongted Das, et al. · Bone Marrow Transplantation · 4
HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma
2025 · Elizabeth Hughes, Sue Latham, et al. · International Journal of Molecular Sciences · 3
PDF
A Longitudinal Evaluation of Euroflow and Combined Quantitative Immunoprecipitation (QIP) and Free Light Chain (FLC) Mass Spectometry (MS) in Functional High Risk Multiple Myeloma
2019 · Andrew Spencer, Tiffany Khong, et al. · Blood · 3
A retrospective study of the utility of desmopressin (1‐deamino‐8‐ D ‐arginine vasopressin) trials in the management of patients with von Willebrand disorder
2009 · J. Shortt, S. S. Opat, et al. · International Journal of Laboratory Hematology · 3
PDF
Immunological markers for prognostication in cytogenetically normal acute myeloid leukemia
2015 · Victoria Y. Ling, Denise Lee, et al. · American Journal of Hematology · 2
PDF
Evaluation of Easym, a Clonotypic Mass Spectrometry Assay, and Euroflow Minimal Residual Disease Assessment in Multiple Myeloma
2023 · Jessie Zhao, Tiffany T. Khong, et al. · Blood · 1
PDF
Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy - Final Analysis from the Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial
2021 · Rose Turner, Hang Quach, et al. · Blood · 1
A dimorphic blast population demonstrates Philadelphia-positive mixed phenotype acute leukaemia
2014 · Victoria Y. Ling, Meaghan Wall, et al. · Pathology · 1
Peripheral blood CD34 donor chimerism and flow cytometry for measurable residual disease are complementary assays for predicting relapse of AML after allogeneic transplantation in AML
2025 · Michael Ashby, Michael Swain, et al. · Blood
T-cell clonality assessment by flow cytometry using anti-TCR-Cβ-1: A tertiary hospital experience
2022 · Chow Yee Lai, Malgorzata Gorniak, et al. · Pathology
Tandem measurable residual disease assessment by 10-colour multiparameter flow cytometry and quantitative polymerase chain reaction in core-binding factor and NPM1-mutated acute myeloid leukaemia
2022 · Jessie Zhao, Malgorzata Gorniak, et al. · Pathology
Utilisation of liquid biopsies in functional high-risk myeloma demonstrates a unique mutational pattern and extensive spatial heterogeneity
2019 · Andrew Spencer, Kawa choi, et al. · Clinical Lymphoma Myeloma & Leukemia
Pf604 the Australasian Leukaemia and Lymphoma (allg) Group Mm17 Trial: Response Adaptive Salvage With Carfilzomib‐thalidomide‐dexamethasone for Multiple Myeloma Patients Failing Front‐line Bortezomib
2019 · A. Spencer, H. Quach, et al. · HemaSphere
Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy
2018 · Andrew Spencer, Hang Quach, et al. · Blood
Works count: 29
Citation count: 339
H-index: 8
I10-index: 6
Year
Topic
Type